Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib.

Mustafa BuyukkorFatih TayOzturk Ates

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)

To our knowledge, these are the only reported cases diagnosed as ALK ( + ) NSCL CA who received favipiravir because of COVID-19 while using TKI, and both patients recovered completely without any side effects.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
healthcare
prognostic factors
coronavirus disease
sars cov
mental health